Yann Foricher
Company: Sanofi
Job title: Head of Small Molecules Medicinal Chemistry
Bio:
Yann is currently the Head of Small Molecules Medicinal Chemistry Department in France within Integrated Drug Discovery Research Platform at Vitry sur Seine Sanofi R&D site. His research unit is involved from target validation to development candidate in Oncology, Immuno-Inflammation and Rare & Neurologic Diseases. He has been taking growing responsibilities within the Medicinal Chemistry community between Vitry sur Seine and Chilly Mazarin Sanofi R&D site over last 14 years. Prior to Vitry sur Seine, he was a project and group leader in medicinal chemistry for the Early to Candidate Unit at Strasbourg Sanofi site where he started as a medicinal chemist in 2004. He is a highly experienced project leader from target validation with tool compound up to development candidate with track records and involved as a MedChem expert in numerous due diligences and key contributor in term of innovation within the Small Molecules Community at Sanofi R&D. Before Sanofi, he worked on the development of new Vitamin E process in Chemical Development Department at DSM Nutritional Product (in 2003-2004, Switzerland). After his diploma of chemical engineering from “Ecole Nationale de Chimie de Mulhouse” (France), he obtained a PhD in Organic Synthesis in with Professor J. Mann(University of Reading/Queen’s University at Belfast, UK) and followed with a postdoc with Professor J. Clayden (University of Manchester, UK).
Seminars:
Panel Discussion: Building Strategic Collaborations & Investment Pathways to Accelerate RNA-Targeted Drug Discovery Across Biotech & Pharma 8:45 am
• Discussing the importance of pharma-biotech-academic collaborations and what each sector can provide to successfully create RNA-targeted therapeutics • How are large pharma and biotech companies structuring risk-sharing partnerships to access innovation and accelerate RNA-targeted therapeutic pipelines • How can early-stage companies leverage academic collaborations, tool compound sharing and co development deals to validate targets…Read more
day: Conference Day Two